ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Early, Short Course Of Hormonal Therapy May Allow Patients To Live Longer

January 25, 2008

Interview: Von Eschenbach Says His Goal Is to Speed Development of Interventions

March 29, 2002

New Health Bills Could Affect Cancer Program

February 9, 1979

Concepts for New, Recompeted DCCP Contracts Approved

June 12, 1981

NIH To Fund Fewer Grants This Year, But Reduce Cuts to Individual Awards.

February 8, 2008

FDA’s Kweder cites Society of Professional Journalists’ Code of Ethics–incorrectly, SPJ says.

March 4, 2005